| Literature DB >> 34229681 |
Zhiyuan Wu1,2, Di Zhou1, Yue Liu1, Zhiwei Li1, Jinqi Wang1, Ze Han1, Xinlei Miao1, Xiangtong Liu1, Xia Li3, Wei Wang2, Xiuhua Guo4,5, Lixin Tao6,7.
Abstract
BACKGROUND: Cross-sectional studies have reported that insulin resistance (IR) is associated with arterial stiffness. However, the relationship between IR and arterial stiffness progression remains unclear. This study aims to evaluate the association of triglyceride glucose (TyG) index and triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio with arterial stiffness progression in a non-normotensive population.Entities:
Keywords: Arterial stiffness; Cohort study; Hypertension; Insulin resistance; TG/HDL-C ratio; Triglyceride glucose index
Mesh:
Substances:
Year: 2021 PMID: 34229681 PMCID: PMC8262008 DOI: 10.1186/s12933-021-01330-6
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Fig. 1Flow chart of the study population
Characteristics of the study population
| Characteristics (N = 1895) | |
|---|---|
| At baseline | |
| Age (years) | 61.90 (12.75) |
| Sex (men, %) | 1477 (77.9) |
| Occupation (n, %) | |
| Manager | 392 (20.7) |
| Technician or professional | 214 (11.3) |
| Worker | 187 (9.9) |
| Retired | 1102 (58.1) |
| BMI | 26.52 (3.22) |
| Physical activity (n, %) | 964 (50.9) |
| Smoking status: none/former/current (n, %) | 1128 (59.6)/285 (15.0)/482 (25.4) |
| Current drinking (n, %) | 844 (44.5) |
| SBP (mmHg) | 139.64 (12.69) |
| DBP (mmHg) | 78.67 (10.06) |
| MAP (mmHg) | 98.99 (8.60) |
| Hypertension (n, %) | 1013 (53.5) |
| Antihypertensive medication (n, %) | 267 (26.4) |
| Diabetes (n, %) | 323 (17.0) |
| Dyslipidaemia (n, %) | 773 (40.8) |
| FBG (mmol/L) | 5.79 (1.48) |
| PBG (mmol/L) | 7.72 (2.61) |
| HbA1c (%) | 5.94 (0.82) |
| Triglyceride (mmol/L) | 1.86 (1.62) |
| Total cholesterol (mmol/L) | 4.81 (0.98) |
| LDL-C (mmol/L) | 3.11 (0.88) |
| HDL-C (mmol/L) | 1.25 (0.32) |
| eGFR (mL/min per 1.73 m2) | 90.88 (26.05) |
| Uric acid (μmol/L) | 365.83 (84.67) |
| Homocysteine (μmol/L) | 12.74 (7.66) |
| TyG index | 1.42 [1.03,1.83] |
| TG/HDL-C ratio | 1.22 [0.78,1.96] |
| baPWV (cm/s) | 1538.00 [1392.00,1769.50] |
| At last visit of follow up | |
| baPWV (cm/s) | 1603.00 [1412.00,1815.50] |
| Change of baPWV (cm/s) | 46.00 [− 251.00,309.50] |
| Change rate of baPWV (cm/s/year) | 9.00 [− 57.22,64.29] |
| Slope of baPWV | 8.11 [− 54.72,66.96] |
| Hypertension (n, %) | 1348 (71.1) |
| Antihypertensive medication (n, %) | 562 (41.7) |
| Antidiabetic medication (n, %) | 151 (8.0) |
| Lipid-lowering medication (n, %) | 273 (14.4) |
Data are the mean (SD), median [IQR] or number (%)
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; FBG: fasting blood glucose; PBG: postprandial blood glucose; HbA1c: glycated haemoglobin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate; TyG: triglyceride glucose; baPWV: brachial-ankle pulse wave velocity
Fig. 2The regression line of the TyG index and TG/HDL-C ratio with artery stiffness progression. A TyG index and baPWV change; B TyG index and baPWV change rate; C TyG index and slope of baPWV; D TG/HDL-C ratio and baPWV change; E TG/HDL-C ratio and baPWV change rate; F TG/HDL-C ratio and slope of baPWV
Association of the TyG index with the absolute change, change rate and slope of baPWV
| model 1 | model 2 | model 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| β | 95% CI | P value | β | 95% CI | P value | β | 95% CI | P value | |
| Change of baPWV (cm/s) | |||||||||
| TyG (continuous) | 32.034 | 4.642–59.425 | 0.022 | 57.119 | 22.835–91.402 | 0.001 | 149.582 | 90.823–208.342 | < 0.001 |
| Quartile 2 (ref: quartile 1) | 59.745 | 10.509–108.982 | 0.017 | 61.086 | 12.582–109.59 | 0.014 | 76.297 | 28.63–123.964 | 0.002 |
| Quartile 3 | 85.613 | 36.416–134.81 | 0.001 | 93.631 | 43.889–143.373 | < 0.001 | 102.562 | 52.08–153.044 | < 0.001 |
| Quartile 4 | 74.957 | 25.494–124.42 | 0.003 | 98.555 | 37.584–159.526 | 0.002 | 129.525 | 58.723–200.326 | < 0.001 |
| P for trend | 0.002 | < 0.001 | < 0.001 | ||||||
| Change rate of baPWV (cm/s/year) | |||||||||
| TyG (continuous) | 11.892 | 3.415–20.368 | 0.006 | 17.974 | 7.307–28.642 | 0.001 | 40.372 | 21.853–58.891 | < 0.001 |
| Quartile 2 (ref: quartile 1) | 11.870 | -3.385–27.125 | 0.127 | 12.122 | -2.986–27.229 | 0.116 | 16.529 | 1.507–31.551 | 0.031 |
| Quartile 3 | 20.615 | 5.373–35.858 | 0.008 | 22.642 | 7.149–38.135 | 0.004 | 24.390 | 8.481–40.299 | 0.003 |
| Quartile 4 | 24.616 | 9.291–39.941 | 0.002 | 30.750 | 11.76–49.741 | 0.002 | 37.607 | 15.294–59.919 | 0.001 |
| P for trend | 0.001 | 0.001 | < 0.001 | ||||||
| Slope of baPWV | |||||||||
| TyG (continuous) | 9.570 | 1.538–17.601 | 0.020 | 14.238 | 4.121–24.355 | 0.006 | 34.874 | 17.238–52.51 | < 0.001 |
| Quartile 2 (ref: quartile 1) | 10.986 | -3.469–25.441 | 0.136 | 10.888 | -3.439–25.215 | 0.137 | 14.872 | 0.57–29.175 | 0.042 |
| Quartile 3 | 18.739 | 4.296–33.182 | 0.011 | 20.092 | 5.399–34.785 | 0.007 | 22.163 | 7.016–37.31 | 0.004 |
| Quartile 4 | 20.126 | 5.604–34.647 | 0.007 | 23.648 | 5.639–41.658 | 0.010 | 30.576 | 9.332–51.82 | 0.005 |
| P for trend | 0.004 | 0.003 | 0.002 | ||||||
Model 1: Adjusted age and sex; Model 2: Age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP at baseline and follow-up; Model 3: Model 2 plus FBG, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow-up
Association of TG/HDL-C ratio with the absolute change, change rate and slope of baPWV
| Model 1 | Model 2 | Model 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| β | 95% CI | P value | β | 95% CI | P value | β | 95% CI | P value | |
| Change of baPWV (cm/s) | |||||||||
| TG/HDL-C ratio (continuous) | 6.795 | − 1.193 to 14.784 | 0.096 | 4.934 | − 3.684 to 13.552 | 0.062 | 37.057 | 7.85–66.264 | 0.013 |
| Quartile 2 (ref: quartile 1) | 70.320 | 21.037–119.604 | 0.005 | 68.883 | 19.964–117.802 | 0.006 | 75.317 | 24.101–126.534 | 0.004 |
| Quartile 3 | 83.153 | 34.299–132.007 | 0.001 | 89.453 | 38.544–140.362 | 0.001 | 84.036 | 25.516–142.556 | 0.005 |
| Quartile 4 | 131.912 | 82.542–181.282 | < 0.001 | 142.938 | 78.525–207.35 | < 0.001 | 133.420 | 51.949–214.891 | 0.001 |
| P for trend | < 0.001 | < 0.001 | 0.002 | ||||||
| Change rate of baPWV (cm/s/year) | |||||||||
| TG/HDL-C ratio (continuous) | 2.587 | 0.115–5.06 | 0.040 | 1.880 | − 0.801 to 4.562 | 0.169 | 9.768 | 0.547–18.989 | 0.038 |
| Quartile 2 (ref: quartile 1) | 14.121 | − 1.149 to 29.392 | 0.070 | 13.621 | − 1.616 to 28.857 | 0.080 | 19.486 | 3.325–35.646 | 0.018 |
| Quartile 3 | 23.979 | 8.842–39.117 | 0.002 | 25.543 | 9.687–41.399 | 0.002 | 29.615 | 11.15–48.08 | 0.002 |
| Quartile 4 | 38.237 | 22.94–53.534 | < 0.001 | 40.369 | 20.307–60.431 | < 0.001 | 43.511 | 17.804–69.217 | 0.001 |
| P for trend | < 0.001 | < 0.001 | 0.001 | ||||||
| Slope of baPWV | |||||||||
| TG/HDL-C ratio (continuous) | 2.253 | − 0.089 to 4.595 | 0.060 | 4.507 | 1.425–6.048 | 0.045 | 7.973 | 0.801–22.317 | 0.035 |
| Quartile 2 (ref: quartile 1) | 12.212 | − 2.264 to 26.687 | 0.098 | 11.300 | − 3.154 to 25.754 | 0.126 | 15.465 | 0.078–30.852 | 0.049 |
| Quartile 3 | 21.636 | 7.287–35.986 | 0.003 | 21.977 | 6.935–37.019 | 0.004 | 24.296 | 6.715–41.877 | 0.007 |
| Quartile 4 | 33.088 | 18.587–47.589 | < 0.001 | 32.178 | 13.146–51.21 | 0.001 | 33.496 | 9.02–57.972 | 0.007 |
| P for trend | < 0.001 | < 0.001 | 0.004 | ||||||
Model 1: adjusted age and sex; Model 2: age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP at baseline and follow-up; Model 3: Model 2 plus HDL-C, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow-up
Fig. 3The distributions of the absolute change, change rate and slope of baPWV among the quartile groups according to the TyG index (A–C) and TG/HDL-C ratio (D–F)
Fig. 4Associations of the TyG index and TG/HDL-C ratio with the absolute change, change rate and slope of baPWV in prehypertensive and hypertensive populations*. *Adjusted for age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, FBG (HDL-C if TG/HDL-C ratio analysed), triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, MAP at baseline and follow up, and use of antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow up